Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus.
Suzuki T, Uchida H, Shibata T, Sasaki Y, Ikeda H, Hamada-Uematsu M, Hamasaki R, Okuda K, Yanagi S, Tahara H.
Suzuki T, et al. Among authors: shibata t.
Mol Ther Oncolytics. 2021 Aug 19;22:265-276. doi: 10.1016/j.omto.2021.08.002. eCollection 2021 Sep 24.
Mol Ther Oncolytics. 2021.
PMID: 34553018
Free PMC article.